for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson, U.S. gov't expand pact to support next phase of COVID-19 vaccine R&D

Nov 14 (Reuters) - Johnson & Johnson and the U.S. Department of Health and Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development, the company said on Saturday.

Under the agreement the company will commit approximately $604 million and the HHS Department’s Biomedical Advanced Research and Development Authority will commit about $454 million to support the Phase 3 ENSEMBLE trial evaluating Janssen’s investigational COVID-19 vaccine candidate as a single dose in up to 60,000 volunteers worldwide, the company said in a statement

Reporting by Sabahatjahan Contractor in Bengaluru Editing by Matthew Lewis

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up